MS DIGEST – Nov. 14, 2014 – The FDA today announced it has approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS.
The approval of was based on two randomized clinical trials comparing Lemtrada to Rebif® (high-dose interferon) where those assessing patients for relapse did not know which drug the patient was receiving.
